Abstract
Five thymol esters were synthesized and characterized using Fourier-transform infrared (FT-IR), 1 H nuclear magnetic resonance (NMR), and 13 C NMR spectroscopy. Their in vitro anticancer activities were evaluated against colorectal (Caco-2), hepatocellular (HepG2), cervical (HeLa), and breast (MCF-7) cancer cell lines, with LX-2 cells used as a non-malignant comparator. Antibacterial activity was assessed against methicillin-resistant Staphylococcus aureus (MRSA), S. aureus , Klebsiella pneumoniae , Escherichia coli , Proteus vulgaris , and Pseudomonas aeruginosa ; antifungal activity was assessed against Candida albicans. J16 showed an IC 50 of 64.97 μg/mL (249.55 μM) against HepG2 cells. J14 showed IC 50 values of 63.36 μg/mL (213.8 μM), 47.38 μg/mL (159.87 μM), and 66.46 μg/mL (224.25 μM) against Caco-2, HeLa, and MCF-7 cells, respectively. The reported IC 50 of J14 in LX-2 cells was 240.82 μg/mL (812.61 μM). J14 showed strong activity against MRSA , S. aureus , and C. albicans , although the organism-specific minimum inhibitory concentrations (MICs) require confirmation against the underlying data. J12 inhibited K. pneumoniae and E. coli at MICs of 0.38 and 0.75 mg/mL, respectively; J12 and J16 inhibited P. vulgaris at 0.38 mg/mL. These in vitro findings suggest that selected thymol esters warrant further investigation. Additional mechanisms, selectivity, and in vivo studies are required before therapeutic conclusions can be drawn.

This publication has 50 references indexed in Scilit: